IL197497A - Non-viral oligonucleotide transport systems - Google Patents

Non-viral oligonucleotide transport systems

Info

Publication number
IL197497A
IL197497A IL197497A IL19749709A IL197497A IL 197497 A IL197497 A IL 197497A IL 197497 A IL197497 A IL 197497A IL 19749709 A IL19749709 A IL 19749709A IL 197497 A IL197497 A IL 197497A
Authority
IL
Israel
Prior art keywords
delivery systems
viral delivery
oligonucleotide non
oligonucleotide
viral
Prior art date
Application number
IL197497A
Other languages
English (en)
Hebrew (he)
Other versions
IL197497A0 (en
Original Assignee
Fmc Biopolymer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Biopolymer As filed Critical Fmc Biopolymer As
Publication of IL197497A0 publication Critical patent/IL197497A0/en
Publication of IL197497A publication Critical patent/IL197497A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL197497A 2006-09-15 2009-03-09 Non-viral oligonucleotide transport systems IL197497A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84472906P 2006-09-15 2006-09-15
PCT/EP2007/059740 WO2008031899A2 (en) 2006-09-15 2007-09-14 Oligonucleotide non-viral delivery systems

Publications (2)

Publication Number Publication Date
IL197497A0 IL197497A0 (en) 2009-12-24
IL197497A true IL197497A (en) 2013-06-27

Family

ID=39092312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197497A IL197497A (en) 2006-09-15 2009-03-09 Non-viral oligonucleotide transport systems

Country Status (9)

Country Link
US (1) US7875449B2 (cg-RX-API-DMAC7.html)
EP (1) EP2061516A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010503640A (cg-RX-API-DMAC7.html)
KR (1) KR20090058562A (cg-RX-API-DMAC7.html)
CN (1) CN101588821A (cg-RX-API-DMAC7.html)
BR (1) BRPI0716925A2 (cg-RX-API-DMAC7.html)
CA (1) CA2662560A1 (cg-RX-API-DMAC7.html)
IL (1) IL197497A (cg-RX-API-DMAC7.html)
WO (1) WO2008031899A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397123A1 (en) * 2006-07-07 2011-12-21 Aarhus Universitet Nanoparticles for nucleic acid delivery
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
WO2013059617A1 (en) * 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
KR20140120316A (ko) 2012-01-27 2014-10-13 에프. 호프만-라 로슈 아게 표적화된 전달을 위한 소분자 인테그린 안타고니스트와 공유 결합된 키토산
KR101601035B1 (ko) * 2013-02-28 2016-03-08 주식회사 종근당 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물
WO2017078054A1 (ja) 2015-11-04 2017-05-11 株式会社ステリック再生医科学研究所 ＲＮＡｉ分子とＮ－アセチル化キトサンとを含む複合体
JP7237825B2 (ja) * 2017-05-26 2023-03-13 公益財団法人川崎市産業振興財団 血中におけるｒｎａの安定性の改善剤および投与方法
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922260A (en) * 1973-08-24 1975-11-25 Quintin P Peniston Process for depolymerization of chitosan
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
SE9904475D0 (sv) * 1999-12-08 1999-12-08 Artursson Nucleic acid delivery system
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
NO317654B1 (no) * 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav.
NO317653B1 (no) * 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
FR2841137B1 (fr) * 2002-06-20 2004-08-13 Bioalliance Pharma Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
EP1594547A2 (en) * 2003-02-14 2005-11-16 University Of South Florida Research Foundation, Inc. Chitosan-microparticles for ifn gene delivery
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
US8399025B2 (en) * 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
EP1948810A4 (en) * 2005-11-04 2010-06-30 Biosyntech Canada Inc COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS
CN102164618A (zh) * 2006-03-30 2011-08-24 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
EP2397123A1 (en) 2006-07-07 2011-12-21 Aarhus Universitet Nanoparticles for nucleic acid delivery

Also Published As

Publication number Publication date
US7875449B2 (en) 2011-01-25
US20080131371A1 (en) 2008-06-05
CA2662560A1 (en) 2008-03-20
KR20090058562A (ko) 2009-06-09
WO2008031899A3 (en) 2008-05-08
EP2061516A2 (en) 2009-05-27
WO2008031899A2 (en) 2008-03-20
CN101588821A (zh) 2009-11-25
JP2010503640A (ja) 2010-02-04
BRPI0716925A2 (pt) 2013-09-17
IL197497A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
IL192629A0 (en) Pesticide delivery system
GB2442875B (en) Regulated drug delivery system
GB2444395B (en) Delivery devices
GB2444394B (en) Delivery devices
IL197516A0 (en) Ester-based polymeric delivery systems
IL200077A0 (en) Transdermal delivery systems
IL198911A0 (en) Drug delivery
EP2029292A4 (en) DISTRIBUTION SYSTEM WITH SURPRISED SPONGE
EP2025123A4 (en) MULTICAST DELIVERY
PL2043543T3 (pl) Układ dostarczania energii
IL205588A0 (en) Vaginal delivery system
ZA201002014B (en) Drug delivery system
GB0707928D0 (en) Delivery system
EP2188002A4 (en) FLUID HANDLING SYSTEM
HUE038832T2 (hu) Kontrasztfolyadék-szállítási rendszer
IL197497A0 (en) Oligonucleotide non-viral delivery systems
ZA200805986B (en) Pesticide delivery system
ZA201000215B (en) Sequential enzyme delivery system
GB2435420B (en) Delivery means
GB2468794B (en) Delivery devices
GB0709390D0 (en) Delivery means
EP2007465A4 (en) RADIONUCLEAR EQUIPMENT DELIVERY SYSTEM
ZA200803511B (en) Hydropower delivery system
GB0617616D0 (en) Message delivery system
GB0616952D0 (en) Delivery

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees